Business
Kiora Pharmaceuticals Announces Publication of Phase 1 Trial Results for KIO-100 as a Treatment for Ocular Inflammatory Disease
Salt Lake City, Utah--(Newsfile Corp. - October 17, 2022) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), ("Kiora" or the "Company") announced that results from
About this update from Kiora Pharmaceuticals, Inc.
[{"type":"text","content":"Salt Lake City, Utah--(Newsfile Corp. - October 17, 2022) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), (\"Kiora\" or the \"Company\") announced that results from a Phase 1 study of KIO-100 (formerly PP-001) demonstrate its potential as a treatment for non-infectious uveitis, an ophthalmic inflammatory disease. The results were published today in a paper titled \"A new small molecule DHODH-inhibitor [KIO-100 (PP-001)] targeting activated T cells for intraocular treatment of uveitis - a phase I clinical trial,\" in the journal Frontiers in Medicine.\nThis first-in-man, open-label, phase-1 clinical trial investigated the use of KIO-100 for treating uveitis, a T cell-mediated, intraocular inflammatory disease. Results showed that a single intravitreal injection of KIO-100 decreased intraocular inflammation in a dose dependent fashion, and improved visual acuity significantly during the duration of the study. The drug was well tolerated, with no serious side effects on intraocular tissues or other adverse events observed.\nKIO-100 is a dihydroorotate dehydrogenase (DHODH) inhibitor, a validated drug target in the treatment of systemic autoimmune conditions. As a third generation DHODH inhibitor with an intravitreal formulation and a high potency for suppressing T and B cells, KIO-100 is a promising non-steroidal anti-inflammatory agent.\n\"The publication of this data is clinical proof-of-concept for using KIO-100 as a safe and effective non-steroidal immune modulator for a wide range of inflammatory eye diseases,\" said Eric Daniels, M.D., Chief Development Officer of Kiora. \"We look forward to building off of these promising results in future clinical studies.\"\nStudy Design and Results\nTwelve adult patients with bilateral chronic, non-infectious intermediate, posterior or pan-uveitis were enrolled and divided into three groups (n=4/group) to receive a single intravitreal injection in the more severely affected eye of 100 µl containing 0.3 µg, 0.6 µg or 1.2 µg KIO-100. All patients were tested at baseline and on days 2, 7, 14, 21 and 28 post-injection. The drug was safe and well tolerated, with one transient increase in intraocular pressure reported in one eye. Consistent with intravitreal injections, mild conjunctival hemorrhages or conjunctival hyperemia were reported at the injection site in all treated eyes. All reported ad...